Holocene Advisors’s Royalty Pharma RPRX Stock Holding History

Holocene Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$265K	Sell	4,728 -4,243	-47%	-$221K	﹤0.01%	780
2026 Q1	$430K	Sell	8,971 -8,409	-48%	-$368K	﹤0.01%	742
2025 Q4	$672K	Sell	17,380 -908	-5%	-$34.6K	﹤0.01%	644
2025 Q3	$645K	Buy	18,288 +7,779	+74%	+$282K	﹤0.01%	666
2025 Q2	$379K	Hold	10,509	–	–	﹤0.01%	713
2025 Q1	$327K	Buy	+10,509	New	+$333K	﹤0.01%	698

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Holocene Advisors's RPRX Position: Q2 2026 in Review

Holocene Advisors reduced its Royalty Pharma (RPRX) stake by 47% in Q2 2026, selling an estimated $221K and leaving 4,728 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #780.

Holocene Advisors first reported a position in RPRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $672K in Q4 2025. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Holocene Advisors held 4,728 shares of Royalty Pharma worth $265K as of Q2 2026.
Holocene Advisors sold 4,243 Royalty Pharma shares in Q2 2026, an estimated $221K.
Royalty Pharma made up ﹤0.01% of Holocene Advisors's portfolio in Q2 2026, its #780 holding.
Holocene Advisors first reported a position in Royalty Pharma in Q1 2025 and has held it in 6 quarters since.
Holocene Advisors's Royalty Pharma position peaked at $672K in Q4 2025.
642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.